| Trade Names: | |
| Synonyms: | |
| Status: | Approved (2018) |
| Entry Type: | Small molecule |
| Molecule Category: | Salt |
| UNII: | V47G1SDI1B |
| Parent Compound: | LOFEXIDINE |
Structure
| InChI Key | DWWHMKBNNNZGHF-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C11H13Cl3N2O |
| Molecular Weight | 295.6 |
| AlogP | 2.76 |
| Hydrogen Bond Acceptor | 3.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 33.62 |
| Molecular species | BASE |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 16.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| AGONIST | Adrenergic receptor alpha-2 agonist | FDA |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Membrane receptor
Family A G protein-coupled receptor
Small molecule receptor (family A GPCR)
Monoamine receptor
Adrenergic receptor
|
- | 4-43 | - | - | - |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Substance Withdrawal Syndrome | 4 | D013375 | FDA |
| Opioid-Related Disorders | 3 | D009293 | ClinicalTrials |
Related Entries
Adverse Reactions
System Organ Classification (SOC)
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL1788132 |
| EPA CompTox | DTXSID0020781 |
| FDA SRS | V47G1SDI1B |
| PubChem | 30667 |
| SureChEMBL | SCHEMBL124601 |
CONTENTS